|Bid||0.85 x 3000|
|Ask||1.08 x 1400|
|Day's Range||0.95 - 1.05|
|52 Week Range||0.41 - 1.90|
|PE Ratio (TTM)||-6.16|
|Earnings Date||May 3, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.25|
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares rise nearly 8% on Friday amid huge volumes.
NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Shares of both Synthetic Biologics and Microbot Medical soared this past Friday after the companies had exciting news to share with investors. Synthetic ...
ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. Synthetic Biologics intends to use proceeds from the Preferred Stock transaction for general corporate purposes, including the continued advancement of SYN-004 (ribaxamase), the Company's Breakthrough Therapy Designation drug candidate designed to prevent antibiotic-mediated C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR) in the gut microbiome.